Answers are grounded in this paper and cite their sources.
Background/Objectives: Aromatase inhibitors have been reported to increase predicted adult height (PAH) in adolescent boys, but their long-term skeletal safety remains uncertain. This study described changes in PAH and in metacarpal cortical bone indices during anastrozole treatment. Methods: This retrospective single-centre cohort study included 30 pubertal boys with short stature and/or compromised predicted adult height prescribed anastrozole 1 mg daily for 24 months at a tertiary centre between January 2018 and December 2022. PAH, bone age, metacarpal index (MCI) standard deviation score (SDS) and bone health index (BHI) SDS were assessed at baseline, 12 months and 24 months by automated digital radiogrammetry. Changes from baseline to 24 months were analysed with paired t-tests. Results: Mean age at baseline was 13.3 ± 1.4 years, and mean bone age was 13.4 ± 1.6 years. Mean height gain over 24 months was 15.2 ± 5.2 cm. PAH increased by 4.4 ± 3.5 cm (95% confidence interval: 3.1–5.7; p < 0.001). Bone age SDS decreased from 0.11 to −0.15 (p = 0.03). MCI SDS increased from −0.97 to −0.42 (p < 0.001), and BHI SDS from −0.97 to −0.71 (p = 0.024). No adverse skeletal events were identified in the available routine clinical records. Conclusions: In this uncontrolled cohort, PAH and metacarpal cortical bone indices increased during anastrozole treatment. Given the retrospective design and reliance on predicted rather than final adult height, these findings are hypothesis-generating and require prospective controlled confirmation, including axial skeletal assessment.
No takes yet. Share an insight, caveat, or question.
Ghanim et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: